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METHODOLOGY
Lymph node pooling: a feasible 
and efficient method of lymph node molecular 
staging in colorectal carcinoma
Natalia Rakislova1†, Carla Montironi1†, Iban Aldecoa1, Eva Fernandez1, Josep Antoni Bombi1, Mireya Jimeno1, 
Francesc Balaguer2, Maria Pellise2, Antoni Castells2 and Miriam Cuatrecasas1,3* 
Abstract 
Background:  Pathologic lymph node staging is becoming a deficient method in the demanding molecular era. 
Nevertheless, the use of more sensitive molecular analysis for nodal staging is hampered by its high costs and exten-
sive time requirements. Our aim is to take a step forward in colon cancer (CC) lymph node (LN) pathology diagnosis 
by proposing a feasible and efficient molecular method in routine practice using reverse transcription loop-mediated 
isothermal amplification (RT-LAMP).
Results: Molecular detection of tumor cytokeratin 19 (CK19) mRNA with RT-LAMP was performed in 3206 LNs from 
188 CC patients using two methods: individual analysis of 1449 LNs from 102 patients (individual cohort), and pooled 
LN analysis of 1757 LNs from 86 patients (pooling cohort). A median of 13 LNs (IQR 10–18) per patient were harvested 
in the individual cohort, and 18 LNs (IQR 13–25) per patient in the pooling cohort (p ≤ 0.001). The median of molecu-
lar assays performed in the pooling cohort was 2 per patient (IQR 1–3), saving a median of 16 assays/patient. The 
number of molecular assays performed in the individual cohort was 13 (IQR 10–18), corresponding to the number of 
LNs to be analyzed. The sensitivity and specificity of the pooling method for LN involvement (assessed by hematoxylin 
and eosin) were 88.9% (95% CI 56.5–98.0) and 79.2% (95% CI 68.9–86.8), respectively; concordance, 80.2%; PPV, 33.3%; 
NPV, 98.4%. The individual method had 100% sensitivity (95% CI 72.2–100), 44.6% specificity (95% CI 34.8–54.7), 50% 
concordance, 16.4% PPV, and 100% NPV. The amount of tumor burden detected in all LNs of a case, or total tumor 
load (TTL) was similar in both cohorts (p = 0.228).
Conclusions: LN pooling makes it possible to analyze a high number of LNs from surgical colectomies with few 
molecular tests per patient. This approach enables a feasible means to integrate LN molecular analysis from CC 
specimens into pathology diagnosis and provides a more accurate LN pathological staging with potential prognostic 
implications.
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Background
Colorectal cancer (CRC) is one of the most prevalent 
malignancies and the second cause of death from can-
cer in developed countries [1]. Importantly, up to 25% 
of curative-intended surgically treated CRC patients 
develop local recurrence or distant metastases within 
5  years of surgery [2–5]. Overall and disease-free sur-
vival rates after curative surgical treatment depend on 
the T and N stages of disease [6–9], but lymph node (LN) 
status is the most powerful prognostic factor [4, 10–12]. 
Thus, pathological analysis of at least 12 LNs from surgi-
cal colectomies is required to ensure a reliable pN0 stage 
and is among the key quality measures for CRC care [13]. 
Moreover, the accuracy and predictive value of assigning 
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stage II are directly proportional to the number of LNs 
examined [14].
Molecular LN assessment to detect tumor burden is far 
more sensitive than the standard hematoxylin and eosin 
(H&E) analysis [15–19]. Whereas molecular methods can 
analyze the entire LN, <0.5% of the LN is histologically 
examined. Thus, pathological nodal staging (pN) may not 
be representative of the LN status and can lead to false 
negative diagnoses [16, 19, 20].
The use of more sensitive molecular methods of LN stag-
ing, rather than H&E, would be strongly recommended 
in stage I–II CRC to help identify those patients at risk of 
recurrence [16–21]. In addition, recently implemented CRC 
screening programs result in earlier stage tumor detection 
[22, 23]. In this setting, a more accurate diagnosis and stag-
ing is mandatory. However, given the high prevalence of 
CRC and the high number of LNs to be analyzed, system-
atic molecular LN analysis or additional diagnostic methods 
beyond routine H&E are far from being incorporated into 
pathological diagnosis, mostly because of the high cost of 
molecular techniques and the supplementary workload.
The molecular assay One Step Nucleic Acid Ampli-
fication (OSNA; Sysmex Corporation, Kobe, Japan) is 
an automated, quantitative and high-sensitive assay 
for detection of cytokeratin 19 (CK19) messenger RNA 
(mRNA). It uses the reverse transcription loop-mediated 
isothermal amplification method (RT-LAMP) to amplify 
CK19 mRNA from LN tissue lysates. The assay has been 
validated for breast and CRC lymph node assessment, 
providing results comparable to extensive histological 
and immunohistochemical (IHC) LN analyses [15, 24–
26]. Additionally, it makes it possible to obtain the total 
tumor load (TTL), defined as the sum of CK19 mRNA 
copies/µL from each positive LN. The TTL corresponds 
to the amount of tumor burden present in all the LNs of a 
surgical specimen [26–28].
In this study we compared two methods of LN molecu-
lar analysis, the individual analysis of each LN, and the 
new approach consisting in pooling several LNs into 
microcentrifuge tubes for analysis (onwards pooling 
method). We aimed to demonstrate the efficiency of 
the new procedure in the analysis of colon cancer (CC) 
LNs in terms of time spent in the molecular analysis, as 
well as the feasibility of introducing this approach into 
pathology daily practice. Molecular LN staging provides 
a practical approach for a more accurate diagnosis, which 
would enable the use of molecular data in CRC patient’s 
therapeutic management.
Results
Patients and lymph node characteristics
A total of 3206 LNs from 188 colectomy specimens of 
surgically treated CC patients were analyzed by OSNA; 
1757 LNs from 86 patients were analyzed using the pool-
ing approach (pooling cohort), and 1449 LNs from 102 
patients were analyzed using individual LN analysis (indi-
vidual cohort). The pooling cohort had more high grade 
cases (p < 0.001), with higher rates of vascular and peri-
neural invasion (p =  0.045 and p =  0.013, respectively) 
and more advanced pT stages (p  =  0.004). In addition, 
it also harbored higher yields of fresh and total LNs 
(p  <  0.001). The differences among the two cohorts are 
due to the fact that the pooling cohort is more recent and 
all tumors were included irrespective of the gross appear-
ance of LNs. The individual cohort is older and cases 
with grossly positive LNs cases were discarded, in an 
effort to obtain pN0 cases for molecular correlation. All 
positive LN cases with H&E corresponded to histological 
findings. Tables 1 and 2 show baseline characteristics of 
patients included in the study.  
All primary tumors resulted positive for CK19 
immunohistochemistry.
Comparison of OSNA and H&E results
In the pooling cohort, 16 out of 77 (20.8%) cases that were 
pN0 with H&E, resulted positive with OSNA. In contrast, 
only one of the 9 cases with positive LNs observed with 
H&E was OSNA negative (11.1%). Therefore, at patient 
level, the sensitivity and specificity of the OSNA-pooling 
method compared to H&E were, respectively, 88.9% (95% 
CI 56.5–98.0) and 79.2% (95% CI 68.9–86.8), with a con-
cordance of 80.2% (Table 2). The OSNA-pooling PPV and 
NPV were 33.3 and 98.4%, respectively.
In the individual cohort, all 10 positive H&E cases were 
also OSNA positive. Among 92 H&E pN0 patients, 51 
(55.4%) were positive with the OSNA analysis. The sen-
sitivity and specificity of the individual LN-OSNA analy-
sis with respect to H&E were, respectively, 100% (95% CI 
72.2–100) and 44.6% (95% CI 34.8–54.7), with a concord-
ance of 50%, PPV of 16.4%, and NPV of 100%.
Overall, the OSNA analysis is very sensitive, and a 
negative result is highly reliable. On the other hand, the 
pooling method has a better concordance with the H&E 
status, mainly as it harbors a much higher PPV.
Molecular assays and time saved
The median of LNs harvested per patient and analyzed 
by OSNA in the pooling cohort was 18 (13–25). All LNs 
were put into a median of 2 tubes (1–3) per case, saving 
16 (12–22) molecular tests per case. On the other hand, 
the median fresh LNs harvested in the individual cohort 
was 13 (10–18), corresponding to the number of molecu-
lar tests performed in this group.
Additionally, the time spent in the process of molecu-
lar analysis was greatly reduced. Each run of the RD-100i 
system analyzes 4 tubes simultaneously in 30–40  min, 
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including LN tissue preparation and analysis. With the 
pooling method a median of two tubes were collected per 
patient. Two patients could be analyzed at each run of the 
OSNA assay in 30–40  min, compared to 135–180  min 
spent per patient to analyze a median of 18 tubes/patient 
if the LN individual analysis was to be used. Given the 
reduction of a median of 16 tubes per patient, the time 
saved in the molecular tests would be 120–160 min per 
patient.
Total tumor load (TTL)
The median TTL of positive cases form the pooling 
cohort was 5485 CK19 mRNA copies/µL (855; 26,350), 
and in the individual cohort it was 1940 copies/µL (920; 
7400), with no significant differences between both 
groups (p = 0.228). In each group, there was no signifi-
cant correlation between the number of histologically 
positive LN and the TTL, or between the number of LN 
analyzed and the TTL.
Among pN0 cases, in the pooling group there were 
16/77 (20.7%) pN0 patients with positive OSNA results 
with a median TTL of 1550 copies/µL (IQR 465–6035). 
In the individual cohort, 51/92 (55.4%) pN0 patients 
resulted OSNA positive, with a median TTL of 1540 cop-
ies/µL (IQR 620–3600). The TTLs of H&E pN0 cases 
from both groups were similar (p = 0.837).
Analysis of the pooling method
In 44 of the 86 cases from the pooling cohort, all LN from 
each colectomy specimen were collected in one tube. In 
the other 42 cases, all LN were collected in more than 
one tube; i.e. 2–7 tubes. We used the latter 42 cases to 
perform a validation assessment in order to evaluate 
whether the TTL obtained from the sum of each of the 
tubes was equivalent to the TTL resulting from the anal-
ysis of the content of all tubes together in a single tube 
(Fig. 1; Table 3).
Our results confirmed that the TTL resulting from the 
sum of the analysis of each tube separately was equiva-
lent to the TTL obtained from the analysis of the content 
Table 1 Patient’s demographics and specimen characteris-
tics from the two cohorts
Clinical parameter n (%)/median (IQR) p value
OSNA pooling 
cohort
OSNA individual 
cohort
Cases 86 (100) 102 (100)
 Gender 0.974
  Male 55 (64.0) 65 (63.7)
  Female 31 (36.0) 37 (36.3)
 Age (years) 70.0 (63.0–79.0) 65.5 (59.0–72.0) 0.0635
Tumor character-
istics
 Size (cm) 3.0 (1.7–4.5) 2.5 (1.1–3.7) 0.992
 Location 0.090
  Right colon 39 (45.3) 51 (50.0)
  Flexures/trans-
verse
1 (1.2) 7 (6.9)
  Left colon 46 (53.5) 44 (43.1)
 Gross configura-
tion
0.821
  Polypoid 57 (66.3) 66 (64.7)
  Ulcerated 29 (33.7) 36 (35.3)
 Grade <0.001
  High 49 (57.0) 26 (25.5)
  Low 37 (43.0) 76 (74.5)
 Type of tumor 0.118
  Adenoma 6 (7.0) 8 (7.8)
  Carcinoma 
in situ
6 (7.0) 17 (16.7)
  Adenocarci-
noma
74 (86.0) 77 (75.5)
 Budding 0.650
  Absence 13 (17.6) 14 (18.7)
  Low grade 47 (63.5) 51 (68.0)
  High grade 14 (18.9) 10 (13.3)
 Vascular invasion 0.045
  No 65 (75.6) 91 (89.2)
  Yes 21 (24.4) 11 (10.8)
 Perineural inva-
sion
0.013
  No 76 (88.4) 98 (96.1)
  Yes 10 (11.6) 4 (3.9)
 Tumor deposits 0.165
  No 81 (94.2) 100 (98.0)
  Yes 5 (5.8) 2 (2.0)
 pT 0.004
  pT0 6 (7.0) 8 (7.8)
  pTis 6 (7.0) 17 (16.7)
  pT1 9 (10.4) 26 (25.6)
  pT2 16 (18.6) 19 (18.6)
  pT3 32 (37.2) 24 (23.5)
  pT4a 17 (19.8) 8 (7.8)
Lymph nodes
IQR interquartile range, LN lymph node, FFPE formalin-fixed paraffin-embedded, 
p-value: using t test for continuous variables and Chi square for categorical 
variables
Table 1 continued
Clinical parameter n (%)/median (IQR) p value
OSNA pooling 
cohort
OSNA individual 
cohort
 Total LN 1992 (100) 1828 (100)
  Fresh LN 1757 (88.2) 1449 (79.3)
  FFPE LN 235 (11.8) 379 (20.7)
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of all tubes mixed into a separate tube, with a sensitivity 
of 83.3% (95% CI 50.9–97.1), a specificity of 93.3% (95% 
CI 76.5–98.8), an agreement of 90.5% (95% CI 76.5–96.9), 
and a substantial correlation (k  =  0.756). Discordant 
cases corresponded to very low TTL values, close to the 
positivity of the test of 250  copies/uL, which could be 
attributed to pipetting differences.
Discussion
In this study, we used a highly sensitive molecular assay 
for the detection of tumor burden in a large number of 
LNs from CC patients. We showed that the pooling strat-
egy is an efficient and rapid method that makes it pos-
sible to perform molecular analysis of multiple LNs at 
the same time, saving time and laboratory resources. This 
method can be easily introduced into the daily practice of 
pathology departments.
The need to process CRC lymph nodes using more sensi-
tive methods than H&E has been unmet so far, given the 
evidence of an increased risk of recurrence and poor sur-
vival associated with the presence of undetected tumor 
burden with H&E in regional LNs of CRC patients [16–21]. 
It is time for an upgrade of the classical H&E LN diagnosis 
and staging, which is becoming obsolete due to its low sen-
sitivity in detecting the presence of tumor burden within 
LNs, mostly as a result of sampling bias and the limited 
amount of LN tissue analyzed [5, 16–20, 29]. As has been 
stated in various studies and meta-analyses, this problem 
could be solved by using molecular methods [16–21].
Although stage I–II CRC patients without nodal inva-
sion or distant metastases have a 93% 5-year survival 
rate, 15–20% of patients histologically staged as pN0 
may recur within 5 years of curative-intended surgery [5, 
12, 13, 30, 31]. The importance of a precise pathological 
nodal staging is critical in determining the most suit-
able treatment and identifying those individuals at risk of 
recurrence [32, 33].
The OSNA assay is an automated, quantitative, rapid, 
and standardized method used in pathology departments 
for breast sentinel LN analysis [27, 34–36]. Authors such 
as Castellano et al. [36] showed that it can provide use-
ful data to decide to perform or spare axillary dissection 
intraoperatively. Its main advantages are that LNs can be 
entirely analyzed, and that it allows the use of the TTL to 
quantify the total amount of tumor burden present in all 
LNs from a surgical specimen.
We propose the use of LN pooling for the assessment 
of molecular LN staging in CC as a practical and novel 
method of multiple LN analysis. In our hands, the OSNA 
pooling analysis yielded better correlation with H&E LN 
status than the individual approach; it showed a higher 
PPV than the individual cohort (33.3 vs 16.4%), with 
similar NPV (98.4 vs 100%). The concordance between 
the OSNA pooling method and the H&E LN status was 
above 80%.
OSNA positivity rates of pN0 CRC patients are vari-
able in previous reported studies [15, 26, 28, 37–41]. 
In our series, among pN0 cases, OSNA detected tumor 
Table 2 Lymph node characteristics and OSNA results
IQR interquartile range, FFPE formalin-fixed, paraffin embedded, LN lymph node
Median (IQR) p-value
OSNA pooling cohort OSNA individual cohort
Fresh LN 18.0 (13.0–25.0) 13.0 (10.0–18.0) <0.001
FFPE LN 1.0 (0.0–5.0) 3.0 (2.0–5.0) <0.001
Total LN 20.5 (17.0–27.0) 17.0 (13.0–22.0) <0.001
H&E results (pN)
 pN0 77 (89.5) 92 (90.2) 0.588
 Positive 9 (10.5) 10 (9.8)
  pN1a 3 (3.5) 5 (4.9)
  pN1b 3 (3.5) 3 (2.9)
  pN1c 0 0
  pN2a 1 (1.2) 2 (2.0)
  pN2b 2 (2.3) 0
 OSNA results
  Positive 24 (27.9) 61 (59.8) <0.001
  Negative 62 (72.1) 41 (40.2)
TTL of OSNA positive cases 5485 (855–26,350) 1940 (920–7400) 0.228
OSNA tests 2.0 (1.0–3.0) 13.0 (10.0–18.0) <0.001
OSNA tests saved 16 (12–22) –
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burden in LNs of more than 50% cases from the indi-
vidual cohort, with 20.8% being positive in the pool-
ing group. The latter results were similar to other 
published studies [15, 26, 28, 37–41]. Croner and col-
leagues analyzed 1594 LNs from 103 patients and found 
25.2% OSNA positivity. In their study, they performed 
the same LN workout as in our work [28]. Güller et al. 
[37] analyzed 313 LNs from 22 patients with only 15.3% 
OSNA positive pN0 patients. They used only half of the 
LN for OSNA analysis and the other half for extensive 
H&E and IHC workout. In addition, LNs smaller than 
3 mm were not analyzed by OSNA. Similar results were 
obtained by Yamamoto et  al. [26] with an upstaging 
rate of 11.3% in 1925 LNs from 124 pN0 patients, ana-
lyzing with OSNA only 44.5% of all dissected LNs and 
also using half of the LN for molecular analysis. They 
also found that the molecular positivity rate increased 
with the pT stage, from 2% in stage I to 25% in stage IIC. 
The importance of the sampling bias is reflected in these 
studies, with higher positivity rates obtained with the 
increase of the amount of LN tissue and the number of 
LN analyzed.
In LN molecular staging, tumor load quantification can 
become an objective tool that could be used to stratify the 
risk of an individual patient. TTL values from OSNA pos-
itive cases were 5485 copies/µL in the pooling cohort and 
1940  copies/µL in the individual cohort, being lower in 
pN0 patients from both cohorts, i.e. 1540 and 1550 cop-
ies/µL, respectively. Furthermore, Yamamoto et  al. [26] 
found an identical TTL amount of 1550 copies/µL in pN0 
patients. They also observed an increment in the TTL 
with the increase in the number of positive LNs, rising 
to 24,050 copies/µL in pN1 patients and to 90,600 copies/
µL in pN2 patients. Hence, TTL represents a continuous 
value of the amount of tumor burden present in the LNs 
of a given patient, which may be more accurate than the 
number of positive LNs [26, 27, 42]. Accordingly, OSNA 
studies in breast sentinel LNs demonstrated that the TTL 
held higher correlation with the prediction of additional 
axillary metastases than the number of positive sentinel 
LNs [27, 42].
Other authors used a similar model with qRT-PCR and 
found CEA mRNA levels in LNs of stage II CRC patients 
as predictors of prognosis [43]. Yet, using GUCY2C RT-
qPCR, Hyslop found occult tumor burden in 87.5% of 
pN0 LNs, although only 20.9% of patients developed 
recurrent disease [17]. In our study, the rate of pN0 
cases that were OSNA positive in the pooling cohort was 
20.8%, similar to the recurrence rates in stage II CRC 
patients published in the literature [5, 12, 13, 30, 31].
Fig. 1 Lymph node processing for OSNA pooling and individual analysis. First two steps (a, b) are common for both cohorts. a Lymph nodes freshly 
dissected from the mesocolon fat are cut in half; b a 1 mm central slice is put in a cassette and used for FFPE and H&E analysis. The rest of the lymph 
node is put into a microcentrifuge tube for ulterior OSNA analysis; c Individual OSNA analysis: After the process of a, b, each central lymph node 
slice is individually put in a cassette for FFPE and H&E analysis. The rest of the lymph node is put into a microcentrifuge tube for individual OSNA 
analysis. d Pooling analysis: Lymph nodes are identically processed and put together into a microcentrifuge tube and a cassette for OSNA and H&E 
analysis, respectively. e Microcentrifuge tube containing multiple lymph nodes (pool) for simultaneous OSNA analysis
Table 3 Pooling method validation approach
Correspondence of TTL values with two different analysis
Analysis of a mixture of each pool in a 
single tube
Analysis of tubes (pools) 
separately
Positive Negative Total
Positive 10 2 12
Negative 2 28 30
Total 12 30 42
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Establishing cutoff values that hold biological sig-
nificance is mandatory in molecular assays. In CRC, 
Croner tentatively stated a TTL of 4250 copies obtained 
with OSNA as determinant of macrometastasis [28]. 
In breast sentinel LN models, TTL values of 15,000 to 
1.2 × 105 copies of CK19 mRNA have been established 
as the cutoff to help clinicians decide on axillary LN 
dissection [27, 42]. Some authors have designed nomo-
grams correlating different predictive values, as the clini-
cal significance of the TTL may be modulated by other 
pathological factors [44]. Although our results are pre-
liminary and not yet validated, we observed that TTL 
values of at least 7500 copies may hold a predictive value 
of recurrence in CC (AUC  =  0.722; personal commu-
nication). Nevertheless, clinically oriented studies with 
long-term follow up are mandatory to validate these 
data.
The TTL has also been associated not only to the LN 
status, [26] but to different histological risk factors. In 
the present study, the presence of perineural and lym-
phatic invasion were independent factors related to TTL 
in both cohorts (p < 0.001; data not shown). In addition, 
in a recent multicenter study, our group showed a rela-
tionship of the TTL with size and pT stage in low grade 
tumors [45].
The study of multiple LNs at once reduces the molecu-
lar analysis to a single or few tests. This may help lessen 
some technical drawbacks such as the molecular evalu-
ation of a large number of LNs separately, which may 
increase the likelihood of potential false positives. We 
obtained a much better overall accuracy with the H&E 
LN status in the pooling cohort than in the individual 
cohort. Additionally, the TTL of both cohorts did not 
statistically differ, and among pN0 cases, the TTLs were 
almost equal between them, and also with pN0 cases 
from other studies [26]. Thus, the pooling method may 
help to better assess the correct status of LNs in terms 
of LN positivity rates, as well as to provide reliable TTL 
data.
LN pooling also overcomes the second and most 
important drawback involved in performing molecu-
lar LN analysis in CRC, that is the amount of time 
invested in the analysis and the high costs of personnel 
and associated materials required. Patients’ TTL can be 
assessed with few molecular tests, analyzing at least the 
12 LNs required. In our hands, the analysis was reduced 
to a median of only 2 molecular tests per case, and the 
time spent in the analysis was also greatly reduced, sav-
ing about 3 h of LN analysis per patient. The use of the 
pooling method enables the analysis of all LNs from 7.5 
patients in the time needed to analyze one patient using 
the individual LN analysis. This represents a drastic drop 
of more than 85% of time and technical workload saved 
in molecular tests.
Our study has some drawbacks. Firstly, as stated, the 
two cohorts were not completely similar in terms of stage 
and tumor characteristics. In the individual cohort, cases 
with grossly positive LNs were discarded and pN1 cor-
responded to microscopic findings. Contrarily, the pool-
ing cohort also included cases with gross positive LNs, 
as the inclusion criteria was made on the basis that fresh 
LN procurement could be performed. But although the 
pooling cohort had more high-grade cases and higher 
LN yields, it showed better correlation between the 
OSNA assay and the H&E evaluation of the LNs than 
the individual cohort. Secondly, the lack of follow-up of 
the pooling cohort makes it impracticable to interpret 
the significance of its results. Further studies are needed 
to obtain a predictive high-risk scale for stage I–II CC 
patients based on the TTL. As we lack the predictive 
values of the OSNA assay in colon cancer, pN staging is 
still mandatory, and LNs cannot be entirely submitted for 
molecular analysis.
Including in  situ neoplasms and colon adenomas can 
be regarded as an additional drawback. However, there 
are some reports that these neoplasms may exception-
ally harbor risk of metastatic disease [46, 47]. In addi-
tion, studies on circulating DNA have shown that in situ 
lesions may also harbor systemic disease in plasma [48, 
49]. One of them included 85 patients (26 colorectal 
adenomas, 24 CRC and 35 normal patients). They found 
that adenomas had higher levels of total DNA, mito-
chondrial DNA, and Alu 247  bp fragment than nor-
mal controls, with a ROC curve of 0.797 [48]. Another 
study performed BEAMing PCR to detect mutant APC 
circulating DNA in patients with adenomas and meta-
static and localized CRC and found that CRC had higher 
mutant APC DNA than controls. Nevertheless, 1 of the 
11 adenomas had higher mutant APC DNA than controls 
[49]. They hypothesized that these fragments may derive 
from necrotic or apoptotic tumor cell DNA engulfed by 
macrophages and later released to de media [49]. Hence, 
the presence of low tumor burden detected by OSNA 
or other molecular techniques may not hold prognostic 
significance. For this reason, molecular analysis of LNs 
from precursor lesions and in situ neoplasms in our study 
could provide valuable data, as it may help to compare 
these lesions with early colon cancer, and to elucidate 
predictive values in this setting.
We believe that molecular LN staging in CRC per-
formed with the OSNA analysis can replace the cur-
rent pN histological staging in the near future. In order 
to be able to incorporate this new technology into the 
current pathologic staging, two conditions should be 
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accomplished; firstly, to demonstrate that the OSNA 
results correlate with disease recurrence, with ade-
quate positive and negative predictive values. Secondly, 
although the OSNA assay is easy, automated, fast, repro-
ducible, and is already used in pathology departments for 
breast sentinel LN analysis, the high number of LNs to 
be analyzed in CCR, its high costs and time invested in 
molecular analysis were major drawbacks. In this study, 
we introduce the LN pooling approach with the OSNA 
assay to overcome these problems.
Conclusions
In conclusion, our study shows that the OSNA pooling 
makes it possible to analyze a high number of LNs from 
surgical colectomies with few molecular tests per patient. 
It also enables quantification of the amount of tumor 
burden present in LNs, measured as the TTL. We pro-
pose the pooling strategy as a rapid method, which can 
be routinely performed in pathology departments. It ena-
bles the integration of more accurate molecular results 
into pathological LN staging. This would benefit the ther-
apeutic management of patients.
Methods
Aim, design and setting
The aim of the study was to propose a feasible and effi-
cient method that enables the integration of molecu-
lar diagnosis of colon cancer LN into pathology daily 
practice.
We describe the OSNA pooling technique as a labora-
tory procedure and compare the pooling and individual 
methods of OSNA assessment.
Sample size and characteristics
This is an observational study performed at a single ter-
tiary hospital. The Institutional Review Board approved 
the study, and informed consent was obtained from all 
patients. Patients’ demographics and specimen charac-
teristics from both CC cohorts are described in Table 1.
Pooling cohort
All surgically resected colon neoplasms from February 
2015 to December 2015 were included. Inclusion crite-
ria were patients over 18  years old, with primary histo-
logically confirmed colon carcinoma or adenoma with 
positive CK19 IHC. Exclusion criteria were rectal carci-
nomas, metastatic disease, familial adenomatous polypo-
sis, inflammatory bowel disease or other malignancies, 
neoadjuvant therapy or stent-type intraluminal devices, 
extensive gross tumor infiltration of the mesocolon fat, 
and reception of the surgical specimen immersed in for-
malin. Eighty-six patients met the criteria and LN OSNA 
analysis was performed using the pooling method.
Individual cohort
Individual LN OSNA analysis was performed in 102 
colectomies obtained from June 2012 to December 
2013. Inclusion criteria were patients over 18  years 
old, with primary histologically confirmed colon car-
cinoma or adenoma with positive CK19 IHC. Exclu-
sion criteria included rectal carcinomas, metastatic 
disease, synchronous tumors, cN1, familial adenoma-
tous polyposis, inflammatory bowel disease or other 
malignancies, neo-adjuvant chemotherapy or stent-
type intraluminal devices, presence of gross metastatic 
LN or gross tumor infiltration of the mesocolon fat, 
and reception of the surgical specimen immersed in 
formalin.
Study procedure
All lymph nodes were analyzed by two methods, the con-
ventional gold standard H&E and the OSNA assay.
Lymph node harvesting for H&E and deferred OSNA analysis
Lymph node dissection from all colectomy specimens 
was performed as described elsewhere [45]. Briefly, the 
mesocolon fat was detached from the colon wall, and dis-
section of the LNs from the mesocolon was performed 
on an ice-cooled and clean surface. In order to repro-
duce the standard LN H&E diagnosis, which it is usu-
ally performed by analyzing the central part of the LN, 
each LN was cut along the long axis. All LNs were ana-
lyzed by H&E and OSNA, irrespectively of their size. For 
larger LNs, a central 1 mm slice was put into a cassette 
for conventional formalin-fixation paraffin-embedding 
(FFPE) and H&E analysis. For small sized LNs, ½ of the 
LN was submitted for OSNA analysis and the other ½ for 
FFPE and H&E analysis. The rest of the LN was put into a 
microcentrifuge tube for delayed OSNA analysis (Fig. 1a, 
b). The same process was performed for all LN from the 
same patient.
At this point, depending on the cohort (individual or 
pooling), single or several LN were put into microcentri-
fuge tubes for ulterior OSNA analysis (Fig. 1c–e).
Individual OSNA lymph node analysis
Each dissected LN was put into separate microcentri-
fuge tubes for individual OSNA analysis. The tubes were 
stored at −80  °C until delayed OSNA analysis was per-
formed (Fig. 1c).
Lymph node pooling for OSNA analysis
After dissection, LNs were put together into microcen-
trifuge tubes (pool). Each tube contained several LN up 
to 600 mg, which is the maximum loading weight of the 
OSNA assay. The tubes were then stored at −80  °C for 
delayed OSNA analysis (Fig. 1d, e).
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H&E analysis
In both groups, a central 1 mm slice or ½ of the LN was 
FFPE for H&E analysis. In the individual group each LN 
was put into separate paraffin blocks for H&E diagnosis. 
In the pooling group, each paraffin block contained mul-
tiple LN (Fig. 1c, d).
One-step nucleic acid amplification (OSNA) procedure 
and total tumor load (TTL)
Each microcentrifuge tube containing either an indi-
vidual LN or a pool of LN was analyzed with the OSNA 
assay following the manufacturer’s instructions [24]. 
Briefly, harvested LN were homogenized with Lynorhag 
lysis buffer (Sysmex, Kobe, Japan), which stabilizes 
mRNA, protects against ribonucleases, and precipitates 
genomic DNA. After centrifugation, the homogenized 
product was analysed with the RD-100i system (Sysmex 
Corporation, Kobe, Japan), using the ready-to-use Lyno-
amp reaction kit (Sysmex, Kobe, Japan). The OSNA assay 
uses the RT-LAMP technology by which CK19 mRNA 
molecules are rapidly amplified without prior extraction 
or purification of RNA and/or DNA nucleic acids. The 
CK19 mRNA concentration is calculated indirectly via a 
byproduct (magnesium pyrophosphate) of the reaction 
[24, 40, 50, 51].
The results (CK19 mRNA copies/µL) were assessed in 
accordance with the cut-off determined in previous stud-
ies, considering a result of more than 250  copies/µL as 
positive [24, 28]. In the individual cohort the total tumor 
load (TTL) was defined as in breast cancer sentinel LN; 
i.e.; the sum of all the CK19 mRNA copies form all posi-
tive LNs in a given patient [27]. In the pooling cohort, 
the total tumor load of pools was defined as the sum of 
all CK19 mRNA copies from all the tubes analyzed per 
patient, which is the amount of tumor burden present in 
all LN dissected from a colectomy specimen, irrespective 
of it being positive or negative.
Time invested in LN molecular analysis
Each run of the RD-100i system analyses up to 4 tubes 
simultaneously in 30–40 min, which includes preparation 
of the LN tissue: thawing, homogenization centrifuga-
tion, and 16 min of the RT-LAMP reaction.
Pooling validation approach
In order to evaluate whether the final OSNA result 
obtained from the sum of each pool was equivalent to 
the result obtained from analyzing a mixture of the con-
tent of each of the pools in a separate tube (Fig.  2), we 
performed a validation assessment test. We used homog-
enized samples from 42/86 patients having their LN 
pooled in more than one tube (2–7 tubes). To simulate 
the pooling event, 20 µL of the homogenized sample of 
each of the pools was diluted with Lynorhag to a final 
volume of 200 µL and individually analyzed with OSNA 
(Fig. 2 left). In parallel, 20 µL of the homogenized sample 
of each of the tubes from a patient was put into a separate 
tube, diluted with Lynorhag to a final volume of 200 µL, 
and analyzed with OSNA (Fig.  2 right). The results of 
both procedures were compared. As in the regular OSNA 
assay, a result of ≥250 copies/µL was considered positive. 
Discordant results were analyzed twice (Table 3).
CK19 immunohistochemistry
The OSNA assay is based on CK19 mRNA detection. 
CK19 IHC was performed on all primary colon carcino-
mas in order to exclude CK19 negative cases, not suitable 
to OSNA analysis. We used the primary CK19 antibody 
(CK19 mouse monoclonal, clone RCK108; IR615 pre-
diluted. Dako, Denmark), as described in a previous 
study [45]. Positive IHC staining was considered when 
≥10% of the cells presented membrane, with or without 
cytoplasmic staining.
Pathology report and LN staging
Lymph node staging and pathology report were per-
formed from the analysis of H&E stains, according to 
the American Joint Committee on Cancer protocol [52, 
53]. The OSNA results were blind to the pathologist and 
clinician.
Statistical analysis
Standard performance characteristics, including sen-
sitivity, specificity, overall accuracy, positive predictive 
value (PPV) and negative predictive value (NPV), and 
their corresponding 95% confidence intervals (95% CI) 
were calculated to compare the OSNA assay with H&E. 
P-values of <0.05 were considered statistically signifi-
cant. Statistical analysis was performed using SAS 9.2 
(SAS Institute Inc., Cary, N.C.) for Windows. Cohen’s 
kappa coefficient for inter-rater agreement was calcu-
lated; with ≤0 indicating no agreement, 0.01–0.20 as 
none to slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 
0.61–0.80 as substantial, and 0.81–1.00 as almost perfect 
agreement.
Fig. 2 Pooling validation test. The OSNA result obtained from the 
sum of the different tubes containing pools (left side) of LN was equiv-
alent to the OSNA result obtained from the analysis of a sample of the 
content of each tube and analyzed in a separate tube (right side)
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